00013.HK
HUTCHMED (China) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 22.54
+3.02%Year over year
Reported trailing growth
- Revenue
- -8.8%
- EBITDA
- —
- EBIT
- -76.6%
- EPS
- -96.6%
- Free cash flow
- +120.0%
- Operating cash flow
- +162.8%
Forward estimates
Based on analyst estimates
- Revenue
- +42.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.8%
- EBITDA
- —
- EBIT
- +3.6%
- Net income
- +112.9%
- EPS
- +108.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026